Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1983-12-13
1986-04-22
Meyers, Albert T.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514507, 514929, A61K 3135, A61K 31215
Patent
active
045843155
ABSTRACT:
The present invention relates to novel methods of use for known pharmacological anti-allergenic agents including disodiumchromoglycate (DSCG) and related compounds thereof, including generally bis chromones, benzopyrans, oxamic acids and salts or esters of each, preferably lodoxamide, its THAM salt and ethyl ester. All are subsequently included in the term biologues. The methods are for the treatment of pathological cardiovascular ischemic states in animals, particularly humans. Additionally, novel compositions incuding the biologues of the present invention in combination with known vasodilators and feed stuffs are also disclosed.
REFERENCES:
patent: 3419578 (1968-12-01), Fitzmaurice et al.
patent: 3519652 (1970-07-01), Fitzmaurice et al.
patent: 3673218 (1972-06-01), Cairns et al.
patent: 3952104 (1976-04-01), Cairns et al.
patent: 3993679 (1976-11-01), Hall et al.
patent: 4046910 (1977-09-01), Johnson
patent: 4055654 (1977-10-01), Cairns et al.
patent: 4061791 (1977-12-01), Hall et al.
patent: 4067995 (1978-01-01), Wright et al.
patent: 4089973 (1978-05-01), Hall et al.
patent: 4095028 (1978-06-01), Hall et al.
patent: 4119783 (1978-10-01), Hall et al.
patent: 4159273 (1979-06-01), Brown et al.
patent: 4159278 (1979-06-01), Hall et al.
March Index 9th Ed. 1979, pp. 858-859, No. 6429, Nitroglycerin.
Goth et al., "Histamine", Medical Pharmacology, chap. 15, pp. 177-188, 9th ed. C. V. Mosby Co., St. Louis (1978).
The Merck Manual, 13th edition, Merck, Sharp and Dohme Research Laboratories, Rahway, N.J. (1977).
Kloner, R. A. et al., Circulation, vol. 58, pp. 220-226 (1978).
DeBoer et al. "Autoradiographic Method for Measuring the Ischemic Myocardium at Risk: Effects of Verapamil on Infarct size after Experimental Coronary Artery Occlusion", Proc. Natl. Acad. Sci, U.S.A. vol. 77, No. 10, pp. 6119-6123, Oct. 1980, Medical Sciences.
Maroko, P. R. et al. "Factors Influencing Infarct Size Following Experimental Coronary Artery Occlusions", Circulation, vol. 43, pp. 67-82 (Jan. 1971).
Reimer, K. A. et al. Lab. Invest., vol. 40, pp. 633-644 (1979).
Jugdutt, B. I. et al., Circulation, vol. 60, pp. 1141-1150 (1979), and vol. 59, pp. 734-743 (1979).
Hoffman, M. et al., Circulation, vol. 60, II-215A (Abstr.) (1979).
Goth et al. Medical Pharmacology, "Coronary Vasodilators", 9th ed, pp. 408-413, The C. V. Mosby Company, St. Louis, MO (1978).
Nuki, K. et al., "The Inhibition of Mast Cell Degranulation in Monkey Gingiva by Disodium Cromoglycate", J. Periodontal, Res. 10:282-287 (1975).
Goldhaber, P., "Heparin Enhancement of Factors Stimulating Bone Resorption in Tissue Culture", Science 147:407-408 (1965).
Shapiro, S. et al. "Mast Cell Population in Gingiva Affected by Chronic Destructive Periodontal Disease", Periodontics 40:276-278 (1969).
Koivuniemi Paul J.
Meyers Albert T.
Rollins John W.
The Upjohn Company
Thierstein Joan
LandOfFree
Method of treating ischemic states does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of treating ischemic states, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of treating ischemic states will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1915708